MetaCap

enGene Therapeutics (ENGN) vs Protara Therapeutics (TARA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Protara Therapeutics (TARA) has outperformed enGene Therapeutics (ENGN) over the past year, losing 68.6% versus a loss of 75.0%. Protara Therapeutics is the larger company by market cap ($140.4 million vs $116.6 million), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ENGN-75.00%TARA-68.60%
+83%-2%-87%
Nov 21, 20251 yearNov 20, 2026
ENGN-82.35%TARA-58.47%
+202%+52%-98%
Jan 31, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ENGN versus TARA key metrics
MetricENGNTARA
Share price$1.74$2.28
Market cap$116.61M$140.38M
1-day change-1.14%-5.00%
YTD return-80.73%-57.22%
1-year return-75.00%-68.60%
5-year return—-67.80%
EPS (TTM)$-2.07$-1.39
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-117.30M$-57.44M
52-week high$12.25$7.82
52-week low$1.40$2.09
Distance from 52-week high-85.80%-70.84%
Analyst consensusbuystrong_buy
Avg. price target upside+146.55%+1010.96%
Average volume1.12M1.07M
Shares outstanding67.02M61.57M
Employees8146
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About enGene Therapeutics

ENGN stock →

enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 81 employees

About Protara Therapeutics

TARA stock →

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 46 employees

ENGN vs TARA FAQ

Which is bigger, enGene Therapeutics or Protara Therapeutics?

Protara Therapeutics (TARA) is larger, with a market capitalization of $140.38M compared with $116.61M for enGene Therapeutics (ENGN).

Which stock has performed better over the past year, ENGN or TARA?

TARA returned -68.60% over the past 12 months, compared with -75.00% for ENGN (price return, excluding dividends). Past performance does not predict future results.

Are enGene Therapeutics and Protara Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons